Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of extremely early antiretroviral therapy to reduce viral reservoir and induce functional cure of HIV-1 infection
2015-000251-24Phase 3Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of tenofovir, emtricitabine, dolutegravir, abacavir, lamivudine and 3 more in human immunodeficiency virus infection (HIV) and Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Started Jun 2015; status: completed.
02
Drugs
tenofoviremtricitabinedolutegravirabacavirlamivudine
03
Conditions
human immunodeficiency virus infection (HIV)Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2015-000251-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000251-24.